HIGHLIGHTS
SUMMARY
Te direct oral anticoagulants (DOACs) have become preferred over vitamin K antagonists (VKAs), such as warfarin, for stroke prevention in atrial fbrillation (AFib) and also for the prevention and treatment of venous thromboembolism (VTE). There remain clinical scenarios where a DOAC activity level may assist in clinical decision making, such as when suspecting under- or overcoagulation, in preparation for a surgical procedure, or in the setting of bleeding or the need for thrombolysis. Tere remains limited data correlating DOAC levels to bleeding, thromboembolic events, or overall mortality. Tis was a single-centered, institutional review . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.